Treatment of Histoplasmosis with MK-991 (L-743,872) | Zendy

John R. Graybill | Zendy; Laura K. Najvar | Zendy; Eleanor M. Montalbo | Zendy; Francesco Barchiesi | Zendy; Michael Luther | Zendy; Michael G. Rinaldi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Histoplasmosis with MK-991 (L-743,872)

Author(s) -

John R. Graybill,

Laura K. Najvar,

Eleanor M. Montalbo,

Francesco Barchiesi,

Michael Luther,

Michael G. Rinaldi

Publication year - 1998

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.42.1.151

Subject(s) - histoplasmosis , histoplasma , spleen , histoplasma capsulatum , medicine , immunology , biology , pharmacology

BALB/cnu /+ immunocompetent and athymic (nu/nu ) mice were infected intravenously with yeast cells ofHistoplasma capsulatum . Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research